Current Report · Items 1.01 · 8-K
Chrome Holding Co.
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement As previously disclosed, on March 23, 2025, Chrome Holding Co., a Delaware corporation (the “Company”), and certain of its subsidiaries (collectively, the “Filing Subsidiaries” and, together with the Company, the “Debtors”) filed voluntary petitions seeking relief under Chapter 11 of Title 11 of the United States Bankruptcy Code (the “Bankruptcy…
Company context
23andMe is a genetics-led consumer healthcare company empowering a healthier future. For more information, please visit www.23andme.com.
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement
As previously disclosed, on March 23, 2025, Chrome
Holding Co., a Delaware corporation (the “Company”), and certain of its subsidiaries (collectively, the “Filing Subsidiaries”
and, together with the Company, the “Debtors”) filed voluntary petitions seeking relief under Chapter 11 of Title 11 of the
United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court (the “Court”) for
the Eastern District of Missouri (the “Chapter 11 Cases”). The Court previously approved the Debtors’ motion with respect
to the procedures applicable to the marketing and sale of all, substantially all, or some of the Debtors’ assets.
As previously disclosed, on July 14, 2025, the Debtors
sold substantially all of their assets to 23andMe Research Institute (formerly known as TTAM Research Institute) (“TTAM”)
for a total purchase price of $302.5 million in cash, in addition to TTAM’s assumption and payment of certain liabilities. The Debtors’
Lemonaid telehealth business, which includes telehealth services providing medical care, pharmacy fulfillment and, the lab and test ordering
services operated by Lemonaid Health Inc., a Delaware corporation (“Lemonaid Health”) remains owned by the Debtors. As part
of the transaction with TTAM and pursuant to the Court-approved procedures, TTAM agreed to acquire Lemonaid Health for a purchase price
of $2.5 million, subject to higher and better offers.
Following the closing of the transaction with TTAM,
the Company received a higher and better offer from Bambumeta Ventures, LLC, a Delaware limited liability company (“Bambumeta
Ventures”), to acquire Lemonaid Health.
On September 10, 2025, the Company, Lemonaid
Health, Chrome Pharmacy Holdings, Inc., a Delaware corporation (“Pharmacy Holdings” and, together with Lemonaid Health, the
“Lemonaid Companies”), Lemonaid SPV, Inc., a Delaware corporation (the “Purchaser”) and Bambumeta Ventures (the
“Guarantor”) entered into a stock purchase agreement (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase
Agreement, subject to the approval of the Court and upon the terms and subject to the conditions set forth in the Stock Purchase Agreement,
the Purchaser has agreed to purchase (i) 100% of the outstanding capital stock of Lemonaid Health and (ii) 100% of the outstanding capital
stock of Pharmacy Holdings (collectively, the “Shares”) free and clear of liens, claims, encumbrances, and other interests
other than certain permitted encumbrances, and to pay amounts necessary to cure defaults and related losses, if any, under contracts to
be assumed by the Lemonaid Companies or their respective subsidiaries or assumed and assigned to the Purchaser (such cure payments, the
“Cure Payments”). The Purchaser will acquire Lemonaid Health for a total purchase price of $10 million in cash (the “Purchase
Price”), in addition to the Cure Payments, subject to the terms and conditions set forth in the Stock Purchase Agreement (such transaction
contemplated by the Stock Purchase Agreement, the “Sale”). The Guarantor has guaranteed the obligations of the Purchaser to
pay the Purchase Price under the Stock Purchase Agreement. The Purchaser has deposited $2.5 million with the Company as a good faith deposit,
which amount will be credited to the Purchase Price at the closing of the Sale.
The Stock Purchase Agreement contains customary representations,
warranties and covenants of the parties for a transaction involving the acquisition of assets from a debtor in bankruptcy. None of the
representations, warranties or covenants (except for covenants that will be performed after closing) contained in the Stock Purchase Agreement
survive the closing nor does the Stock Purchase Agreement provide for indemnification for any breach of such representations, warranties
or covenants. The completion of the Sale is subject to a number of customary conditions, which, among others, include the entry of an
order of the Court confirming a Chapter 11 plan of reorganization for the Debtors, the occurrence of the effective date of such plan,
the performance by each party of its obligations under the Stock Purchase Agreement, the accuracy of each party’s representations,
and receipt of certain regulatory approvals related to the transfer of pharmacy licenses. The Stock Purchase Agreement contains certain
termination rights for the Company and the Purchaser, including the right for each of the Company and the Purchaser to terminate the Stock
Purchase Agreement if the closing has not occurred on or prior to December 1, 2025 (subject to an extension until January 30, 2026 under
certain conditions as described in the Stock Purchase Agreement).
Additional Information on the Chapter 11 Cases
Court filings and information about the Chapter 11
Cases can be found at a website maintained by the Company’s claims agent Kroll at https://restructuring.ra.kroll.com/23andMe, by
calling (888) 367-7556, or by sending an email to 23andMeInfo@ra.kroll.com. The documents and other information available via website
or elsewhere are not part of this Current Report on Form 8-K and will not be deemed incorporated herein.
Cautionary Note Regarding the Company’s Common Stock
The Company cautions that trading in the Company’s
Class A common stock, $0.0001 par value per share (the “Common Stock”) during the pendency
of the Chapter 11 Cases is highly speculative and poses substantial risks. Trading prices for the Company’s Common Stock may bear
little or no relationship to the actual recovery, if any, by holders of the Common Stock in the Chapter 11 Cases. The Company cannot assure
investors of the liquidity of an active trading market, the ability to sell shares of the Common Stock when desired, or the prices that
an investor may obtain for the shares of the Common Stock.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking
statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. All statements, other than statements
of historical fact, included or incorporated in this document are forward-looking statements. The words “believes,” “anticipates,”
“estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,”
“potential,” “likely,” “projects,” “predicts,” “continue,” “will,”
“schedule,” and “would” or, in each case, their negative or other variations or comparable terminology, are intended
to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking
statements are predictions based on the Company’s current expectations and projections about future events and various assumptions.
The Company cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements
and you should not place undue reliance on the Company’s forward-looking statements. These forward-looking statements involve a
number of risks, uncertainties (many of which are beyond the control of the Company), or other assumptions that may cause actual results
or performance to differ materially from those expressed or implied by these forward-looking statements, which could include the following:
risks and uncertainties relating to the Chapter 11 Cases, including but not limited to, the Company’s ability to obtain Court approval
with respect to motions in the Chapter 11 Cases, the effects of the Chapter 11 Cases on the Company and on the interests of various constituents,
Court rulings in the Chapter 11 Cases (including whether the Stock Purchase Agreement and the Sale will be approved by the Court) and
the outcome of the Chapter 11 Cases in general, the length of time the Company will operate under the Chapter 11 Cases, risks associated
with any third-party motions in the Chapter 11 Cases, the adverse effects of the Chapter 11 Cases on the Company’s liquidity or
results of operations and increased legal and other professional costs necessary to execute the Company’s Chapter 11 Cases; trading
price and volatility of the Common Stock; and the continuation of trading of the Common Stock on the OTC Pink Market, including whether
broker-dealers will continue to provide public quotes of the Common Stock on the OTC Pink Market and whether the trading volume of the
Common Stock will be sufficient to provide for an efficient trading market. The forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described from time to time in the Company’s filings with the U.S. Securities
and Exchange Commission (the “SEC”), including under Item 1A, “Risk Factors” in the Company’s most recent
Annual Report on Form 10-K, as filed with the SEC, and as revised and updated by the Company’s Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The statements made herein are made as of the date of this document and, except as may be required by law,
the Company undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.